|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations.
|
21869714 |
2011 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.
|
28448232 |
2017 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
|
27029623 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that CytoRich Red is not only suitable for ICC with EGFR mutation-specific antibodies, but also for DNA analysis of cytological material, and is useful in molecular testing of lung cancer, for which various types of analyses will be needed in future.
|
24167084 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
By optimizing competitive allele-specific TaqMan PCR (CAST-PCR), we assessed the copy number of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) alleles in the pre/post surgery plasma of 168 lung cancer patients.
|
28382702 |
2017 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, the mutation does not significantly alter the Km for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed.
|
23612964 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for EGFR, ALK and ROS1 genetic mutation analysis in patients with adenocarcinoma or not otherwise specified (NOS) lung cancer.
|
30582673 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to EGFR-TKIs and other targeted therapies.
|
22664249 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies.
|
30679984 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to clarify the correlation between the EGFR mutation status and the prevalence of underlying lung disease in smokers with lung cancer.
|
23467672 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
GMI induced apoptosis in lung cancer cells bearing wild-type and mutated EGFR.
|
29974605 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
|
15284455 |
2004 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms.
|
29967248 |
2018 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer.
|
30580903 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data may suggest that gefitinib should be preferred to erlotinib for the treatment of pregnant woman with lung cancer harboring an EGFR-activating mutation, during the second and third trimesters of pregnancy.
|
25851627 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in the epidermal growth factor receptor (EGFR) occur frequently in lung cancer and confer sensitivity to EGFR kinase inhibitors gefitinib and erlotinib.
|
16540667 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We showed previously that hepatocyte growth factor (HGF) induced gefitinib resistance of lung cancer harboring EGFR-activating mutations.
|
20008840 |
2010 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in patients with multifocal lung adenocarcinomas (LUAC) constitutes a rare molecular subtype of lung cancer.
|
31138506 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR gene mutation testing is feasible on local and interstate lung cancer samples.
|
24720523 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, the development of specific antibodies against EGFR mutation proteins might be useful for the diagnosis and treatment of lung cancer.
|
25525358 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
|
21220474 |
2011 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in exon 19 and exon 21 of EGFR gene were detected in non-amplified genomic DNAs that were isolated from both the lung cancer cell lines and the cancer tissues of non-small cell lung cancer patients.
|
20036793 |
2010 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
|
17311002 |
2007 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A cell-free DNA-based test for EGFR mutations has been approved as an alternative to tumor tissue analysis in lung cancer.
|
27663595 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
|
23588221 |
2013 |